AI assistant
SynAct Pharma — Share Issue/Capital Change 2023
Oct 31, 2023
3114_rns_2023-10-31_d41429c2-840a-420e-8736-ba2d41cf9e0b.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Change in number of shares and votes in SynAct Pharma
During the month of October, the number of shares and votes in SynAct Pharma AB have increased due to the directed issue of shares which was resolved upon by the board of directors on 11 October 2023.
As of 31 October 2023, the total number of shares and votes in SynAct Pharma AB amounts to 35,570,980.
For further information, please contact: Torbjørn Bjerke, MD CEO, SynAct Pharma AB Phone: +46 727 44 41 58 Mail: [email protected] Mail: [email protected]
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.
This information is such information as SynAct Pharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 31 October 2023 at [XX:XX] CET.
This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-10-31 17:31 CET.